Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer
Peeters, M Oliner, K Price, T Cervantes, A Sobrero, A Ducreux, M Hotko, Y André, T Chan, E Lordick, F
Peeters, M
Oliner, K
Price, T
Cervantes, A
Sobrero, A
Ducreux, M
Hotko, Y
André, T
Chan, E
Lordick, F
Citations
Altmetric:
Abstract
We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).
Description
Date
2015-12-15
Publisher
Collections
Keywords
Type
Article
Citation
Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. 2015, 21 (24):5469-79 Clin Cancer Res